SCHEMBL10692630

SCHEMBL10692630

CCc1ccc(Cc2ccccc2C(=O)O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.72
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57
FOLH1 Q04609 1/20 0.53
SLC16A3 O15427 1/20 0.52
ALDH1A1 P00352 3/20 0.50
PTPN1 P18031 4/20 0.49
CLCN2 P51788 1/20 0.49
CYP2C9 P11712 2/20 0.48
HIF1A Q16665 2/20 0.48
PTPN2 P17706 1/20 0.46
PTPN6 P29350 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C19 P33261 1/20 0.46
BLM P54132 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23003 0.87 TSHR (0.79) TSHRCA1CA2CA9FOLH1
SCHEMBL4908158 0.86 TSHR (0.72) TSHRCA1CA2CA9FOLH1
Acetic Acid SCHEMBL28245857 0.85 TSHR (0.71) TSHRCA1CA2CA9FOLH1
SCHEMBL28370887 0.85 TSHR (0.76) TSHRCA1CA2CA9FOLH1
Ammonia Solution, Strong SCHEMBL27527756 0.85 TSHR (0.76) TSHRCA1CA2CA9FOLH1
SCHEMBL7759867 0.84 TSHR (0.74) TSHRCA1CA2CA9FOLH1
SCHEMBL69041 0.84 TSHR (1.00) TSHRCA1CA2CA9FOLH1
SCHEMBL29580520 0.84 TSHR (0.74) TSHRCA1CA2CA9FOLH1
SCHEMBL2292722 0.84 TSHR (0.74) TSHRCA1CA2CA9FOLH1
SCHEMBL28115 0.82 FOLH1 (0.61) TSHRCA1CA2CA9FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280983-B9 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM (FR) 2021-06-09 EP disclosed
US-8486897-B2 C-aryl glycoside compounds for the treatment of diabetes and obesity TFCHEM (FR) 2013-07-16 US disclosed
US-8486897-B2 C-aryl glycoside compounds for the treatment of diabetes and obesity TFCHEM (FR) 2013-07-16 US disclosed
EP-2280983-B1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM (FR) 2013-03-13 EP disclosed
US-20110034402-A1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM 2011-02-10 US disclosed
US-20110034402-A1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM 2011-02-10 US disclosed
WO-2009121939-A2 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY TFCHEM (FR) 2009-10-08 WO disclosed
US-4792551-A 9-anthryloxyaminoalkanes and related compounds as anti-inflammatory and analgetic agents SYNTEX (U.S.A.) INC. (US) 1988-12-20 US disclosed
EP-0132351-A2 9-Anthryloxyaminoalkanes and related compounds, processes for their preparation and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1985-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034402-A1 C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY SLC5A2, SLC5A1, GPR119 TSHR 1386/4885CA1 3447/4885CA2 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.